Kalpit Patel Analyst PerformanceAnalyst at Wolfe ResearchKalpit Patel is a stock analyst at Wolfe Research in the medical sector, covering 26 publicly traded companies. Over the past year, Kalpit Patel has issued 33 stock ratings, including strong buy, buy, hold, and sell recommendations. While full access to Kalpit Patel's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Kalpit Patel's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings41 Last 4 YearsBuy Recommendations60.00% 24 Buy RatingsCompanies Covered26 Unique Companies Ratings Distribution40RatingsDistribution of strong buy, buy, hold, and sell ratings by Kalpit Patel.RatingPercentageCount Strong Buy10.0%4 ratings Buy50.0%20 ratings Hold37.5%15 ratings Sell2.5%1 ratingsOut of 40 total stock ratings issued by Kalpit Patel at Wolfe Research, the majority (50.0%) have been Buy recommendations, followed by 37.5% Hold, 10.0% Strong Buy, and 2.5% Sell.Best & Worst CallsBest Call000.0%KYMRJun 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%GERNFeb 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ26 companiesKalpit Patel, an analyst at Wolfe Research, currently covers 26 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical26 companies100.0%Kalpit Patel of Wolfe Research specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE21 companies80.8%MED - DRUGS5 companies19.2% Kalpit Patel's Ratings History at Wolfe Research Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsKYMRKymera Therapeutics6/29/2026Boost Price Target$106.80$155.00Buy$0.0000.00% ROIMIRMMirum Pharmaceuticals5/19/2026Initiated Coverage$95.49$145.00Outperform$0.0000.00% ROICGONCG Oncology5/19/2026Initiated Coverage$62.93Peer Perform$0.0000.00% ROITYRATyra Biosciences5/19/2026Initiated Coverage$35.66Peer Perform$0.0000.00% ROIMIRMMirum Pharmaceuticals5/19/2026Initiated Coverage$95.65$145.00Outperform$0.0000.00% ROISLNOSoleno Therapeutics4/7/2026Downgrade$52.26Hold$0.0000.00% ROIGMABGenmab A/S3/27/2026Initiated Coverage$26.03$32.00Outperform$0.0000.00% ROIOLMAOlema Pharmaceuticals3/27/2026Initiated Coverage$14.12Peer Perform$0.0000.00% ROIKRYSKrystal Biotech3/27/2026Initiated Coverage$251.40Peer Perform$0.0000.00% ROIONCBeOne Medicines3/27/2026Initiated Coverage$276.95$340.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. CORTCorcept Therapeutics3/26/2026Upgrade$40.47Peer Perform$0.0000.00% ROIAVBPArriVent BioPharma3/23/2026Boost Price Target$22.22$45.00Buy$0.0000.00% ROICELCCelcuity3/12/2026Reiterated Rating$109.43$110.00Outperform$0.0000.00% ROIASNDAscendis Pharma A/S3/2/2026Reiterated Rating$236.07$260.00Outperform$0.0000.00% ROISLNOSoleno Therapeutics1/12/2026Set Price Target$41.50$60.00$0.0000.00% ROISLNOSoleno Therapeutics1/12/2026Reiterated Rating$41.57Outperform$0.0000.00% ROICORTCorcept Therapeutics12/31/2025Downgrade$36.05$30.00Underperform$0.0000.00% ROIKYMRKymera Therapeutics12/22/2025Boost Price Target$83.99$117.00Buy$0.0000.00% ROIPDSBPDS Biotechnology11/25/2025Lower Price Target$0.75$3.00Buy$0.0000.00% ROITNGXTango Therapeutics11/18/2025Initiated Coverage$7.98Peer Perform$0.0000.00% ROISMMTSummit Therapeutics11/18/2025Initiated Coverage$16.95Peer Perform$0.0000.00% ROISLNOSoleno Therapeutics11/18/2025Initiated Coverage$47.25$75.00Outperform$0.0000.00% ROISRRKScholar Rock11/18/2025Initiated Coverage$36.47$42.00Outperform$0.0000.00% ROIRVMDRevolution Medicines11/18/2025Initiated Coverage$69.14$75.00Outperform$0.0000.00% ROIORICOric Pharmaceuticals11/18/2025Initiated Coverage$12.06Peer Perform$0.0000.00% ROIJANXJanux Therapeutics11/18/2025Initiated Coverage$28.72Peer Perform$0.0000.00% ROICORTCorcept Therapeutics11/18/2025Initiated Coverage$75.12Peer Perform$0.0000.00% ROICELCCelcuity11/18/2025Initiated Coverage$92.23$110.00Outperform$0.0000.00% ROIACLXArcellx11/18/2025Initiated Coverage$90.34Peer Perform$0.0000.00% ROICELCCelcuity11/17/2025Upgrade$94.23Strong-Buy$0.0000.00% ROIRVMDRevolution Medicines11/17/2025Upgrade$70.53Strong-Buy$0.0000.00% ROISLNOSoleno Therapeutics11/17/2025Upgrade$47.00Strong-Buy$0.0000.00% ROISRRKScholar Rock11/17/2025Upgrade$39.69Strong-Buy$0.0000.00% ROIKYMRKymera Therapeutics6/3/2025Upgrade$43.13$60.00Buy$00.0000.00% ROIBCYCBicycle Therapeutics5/2/2025Lower Price Target$9.19$14.00Neutral$0.0000.00% ROIAVBPArriVent BioPharma3/20/2025Initiated Coverage$19.60$37.00Buy$00.0000.00% ROIRIGLRigel Pharmaceuticals3/5/2025Boost Price Target$19.49$24.00Neutral$00.0000.00% ROIGERNGeron2/18/2025Lower Price Target$2.63$3.50Buy$0.0000.00% ROIVSTMVerastem1/31/2025Boost Price Target$6.39$9.00Buy$0.0000.00% ROIFHTXFoghorn Therapeutics1/30/2025Initiated Coverage$3.98$10.00Buy$0.0000.00% ROISolar is dead. Here’s what replaces it. (Ad)Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-carbon energy source retains full government backing for eight more years - and it runs around the clock without batteries. Investment in this sector has surged 100x in seven years. The Pentagon named it a top energy priority, California mandated it, and Google, Meta, and Berkshire Hathaway are already under contract. One company controls the entire chain from the ground to the grid.See the last clean energy source with full government backing Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyRoyal Bank Of CanadaWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupDeutsche Bank AktiengesellschaftRaymond James FinancialBMO Capital MarketsNational Bank FinancialBerenberg Bank Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
